Want to see JP:219A full AI Analyst Report?
Top Page
Heartseed, Inc.
(219A)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥2,662.00
▲(47.56% Upside)
Action:Reiterated
Date:08/21/26
The score is primarily supported by the FY2025 financial turnaround (profitability and positive free cash flow) and strong bullish price trend. It is held back by high historical volatility in results (prior multi-year losses/cash burn), technically stretched conditions (overbought signals), and weak/unclear earnings-based valuation due to a negative P/E.
Positive Factors
FY2025 Profitability Turnaround
The sharp FY2025 shift from losses to strong profitability indicates improved operating execution and commercial traction. If maintained, the higher earnings base can strengthen internal funding capacity and reduce reliance on external capital.
Negative Factors
History of Losses and Cash Burn
The prior multi-year loss and cash-burn period shows that performance has been volatile and funding needs can rise during weaker phases. This history increases execution risk and makes the durability of the FY2025 recovery important.
Read all positive and negative factors
Positive Factors
Negative Factors
FY2025 Profitability Turnaround
The sharp FY2025 shift from losses to strong profitability indicates improved operating execution and commercial traction. If maintained, the higher earnings base can strengthen internal funding capacity and reduce reliance on external capital.
Read all positive factors
Heartseed, Inc. (219A) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥53.17B
Dividend YieldN/A
Average Volume (3M)738.74K
Price to Earnings (P/E)―
Beta (1Y)0.98
Revenue GrowthN/A
EPS GrowthN/A
CountryJP
Employees43
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)25.93
Shares Outstanding22,897,400
10 Day Avg. Volume469,170
30 Day Avg. Volume738,736
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)5.17
Price to Sales (P/S)12.93
P/FCF Ratio37.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-94.5
Revenue Forecast (FY)¥451.00M
Heartseed, Inc. Business Overview & Revenue Model
Company Description
Heartseed Inc. is a Japan-based company engaged in research and development of regenerative medicine products. The company has established cardiac regenerative medicine, a therapy in which microtissue derived from iPS cells is transplanted into th...
Heartseed, Inc. Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
| Breakdown | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 |
|---|---|---|---|---|
Income Statement | ||||
| Total Revenue | 3.03B | 873.61M | 344.73M | 499.06M |
| Gross Profit | 3.03B | 0.00 | 0.00 | 0.00 |
| EBITDA | 278.71M | -996.98M | -1.45B | -1.46B |
| Net Income | 163.38M | -812.73M | -1.47B | -1.41B |
Balance Sheet | ||||
| Total Assets | 8.14B | 7.07B | 5.72B | 4.94B |
| Cash, Cash Equivalents and Short-Term Investments | 7.34B | 5.30B | 4.59B | 3.99B |
| Total Debt | 890.00K | 5.39M | 11.58M | 30.98M |
| Total Liabilities | 571.35M | 444.34M | 450.19M | 208.45M |
| Stockholders Equity | 7.57B | 6.62B | 5.27B | 4.73B |
Cash Flow | ||||
| Free Cash Flow | 1.05B | -1.36B | -1.13B | -1.92B |
| Operating Cash Flow | 1.08B | -1.34B | -797.93M | -1.92B |
| Investing Cash Flow | 72.64M | -67.13M | -425.69M | -994.00K |
| Financing Cash Flow | 375.76M | 2.12B | 1.85B | -22.16M |
Heartseed, Inc. Technical Analysis
Positive
1804.00
Price Trends
1746.62
Positive
1744.23
Positive
1805.00
Positive
Market Momentum
167.36
Negative
72.68
Negative
89.27
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:219A, the sentiment is Positive. The current price of 1804 is below the 20-day moving average (MA) of 1946.75, above the 50-day MA of 1746.62, and below the 200-day MA of 1805.00, indicating a bullish trend. The MACD of 167.36 indicates Negative momentum. The RSI at 72.68 is Negative, neither overbought nor oversold. The STOCH value of 89.27 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:219A.
Heartseed, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ¥45.01B | 13.47 | ― | 2.53% | 3.38% | 32.41% | |
69 Neutral | ¥523.53B | 16.25 | ― | 1.28% | 8.72% | 3.45% | |
66 Neutral | ¥53.17B | -84.07 | ― | ― | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ¥15.21B | 16.84 | ― | 2.32% | 8.19% | -25.81% | |
52 Neutral | ¥5.89B | 49.80 | ― | 2.65% | 9.45% | ― | |
42 Neutral | ¥5.72B | -3.59 | ― | ― | ― | 33.26% |
* General Sector Average
JP:219A
Heartseed, Inc.
2,465.00
-1,020.00
-29.27%
JP:2796
Pharmarise Holdings Corp.
500.00
13.11
2.69%
JP:3349
COSMOS Pharmaceutical Corporation
6,569.00
-2,365.16
-26.47%
JP:4350
Medical System Network Co., Ltd.
500.00
37.97
8.22%
JP:4931
Shinnihonseiyaku Co., Ltd.
2,095.00
-290.46
-12.18%
JP:190A
Chordia Therapeutics Inc.
72.00
-105.00
-59.32%
Heartseed, Inc. Corporate Events
Heartseed Secures ¥2 Billion Credit Line to Advance Heart Failure Cell Therapy
Aug 14, 2026
Heartseed Inc. has secured a 2 billion yen special overdraft facility from Sumitomo Mitsui Banking Corporation to support its push toward manufacturing and marketing approval for its lead cardiomyocyte replacement therapy, HS-001. The unsecured, o...
Heartseed Books Subsidy-Driven Non-Operating Gain Without Changing Outlook
Aug 14, 2026
Heartseed Inc. reported non-operating income of 69,833 thousand yen for the six months ended June 30, 2026, driven mainly by a 52,000 thousand yen subsidy tied to the Japan Agency for Medical Research and Development’s program for basic tech...
Heartseed posts interim loss but keeps strong equity base as R&D weighs on 2026 outlook
Aug 14, 2026
Heartseed Inc. reported non-consolidated net sales of ¥467 million for the six months ended June 30, 2026, down from ¥1,919 million in the prior comparable period, and swung to an interim net loss of ¥554 million, versus a previous ...
Heartseed doses first patient in EMERALD trial of HS-005 for dilated cardiomyopathy
Jun 12, 2026
Heartseed Inc. has begun dosing patients in its domestic Phase I/II EMERALD clinical trial of HS-005, an allogeneic iPS cell-derived cardiomyocyte spheroid therapy administered via catheter, in patients with heart failure caused by dilated cardiom...
Heartseed Advances HS-001 Heart Failure Therapy Toward Japan Approval After Positive Trial Readout
Jun 1, 2026
Heartseed Inc. reported results from its Phase I/II LAPiS clinical trial of HS-001, an allogeneic iPS cell-derived cardiomyocyte spheroid therapy for severe ischemic heart failure, confirming that the study’s primary safety endpoint was met ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.